Nitin Sood - Mar 6, 2023 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: Chief Commercial Officer, MRD
Signature: /s/ Nitin Sood by Stacy L Taylor, Attorney-in-Fact
Stock symbol: ADPT
Transactions as of: Mar 6, 2023
Transactions value $: -$141,477
Form type: 4
Date filed: 3/8/2023, 07:01 PM
Previous filing: Nov 1, 2022
Next filing: Aug 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Award	$0	+133K	+116.13%	$0.00	247K	Mar 6, 2023	Direct
transaction	ADPT	Common Stock	Sale	-$57.1K	-6.66K	-2.69%	$8.57	241K	Mar 6, 2023	Direct	F1
transaction	ADPT	Common Stock	Sale	-$84.4K	-9.81K	-4.07%	$8.60	231K	Mar 7, 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADPT	Stock Option (right to buy)	Award	$0	+200K		$0.00	200K	Mar 6, 2023	Common Stock	200K	$8.46	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.
F3	The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.25 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4	The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.